Aprea TherapeuticsAPRE
13F holders, Q1 2024 (March 31)22holders
$6.63avg. 13F price*
At the end of Q1 2024, 22 institutions reported holding Aprea Therapeutics Inc. (APRE) in their 13F filings. The largest holders were AIGH Capital Management LLC ($3.5M), Sio Capital Management, LLC ($1.9M) and Sphera Funds Management LTD. ($1.8M).
- Company
- Aprea Therapeutics Inc.
- CUSIP
- 03836J201
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 6 | $4.2M |
| Exits | 3 | $786K |
Ownership 22 holders
| AIGH Capital Management LLC | 1.69% | Add +54.4% | 539,300 | $3.5M |
| Sio Capital Management, LLC | 0.64% | Reduce -1.2% | 276,603 | $1.9M |
| Sphera Funds Management LTD. | 0.29% | New | 270,000 | $1.8M |
| Nantahala Capital Management, LLC | 0.14% | New | 205,760 | $1.4M |
| DAFNA Capital Management LLC | 0.21% | New | 137,174 | $918K |
| Vanguard Group Inc. | 0.00% | Add +234.3% | 115,978 | $776K |
| Morgan Stanley | 0.00% | Add +55.8% | 26,818 | $179K |
| Geode Capital Management, LLC | 0.00% | Add +15.7% | 20,221 | $135K |
| HighTower Advisors, LLC | 0.00% | New | 13,864 | $93K |
| BlackRock Inc. | 0.00% | No change | 8,504 | $57K |
| Royal Bank of Canada | 0.00% | Reduce -94.2% | 2,570 | $17K |
| Group One Trading LLC | 0.00% | No change | 2,160 | $14K |
| Bank of America Corp. | 0.00% | Reduce -51.8% | 1,566 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +105.5% | 1,126 | $8K |
| PNC Financial Services Group, Inc. | 0.00% | No change | 1,000 | $7K |
| Mb, Levis & Associates, LLC | 0.00% | No change | 806 | $5K |
| Osaic Holdings, Inc. | 0.00% | Add +50.0% | 300 | $2K |
| Wells Fargo & Company | 0.00% | No change | 272 | $2K |
| FMR LLC | 0.00% | New | 161 | $1K |
| WealthCollab, LLC | 0.00% | No change | 158 | $1K |
| Towne Trust Company, N.A | 0.00% | New | 50 | $335 |
| UBS Group AG | 0.00% | No change | 3 | $20 |
"% of holder's portfolio" is APRE's weight in each manager's 13F, not the share of Aprea Therapeutics Inc. the manager owns.